Lartruvo® (olaratumab) – Product withdrawal

- On April 25, 2019, Eli Lilly announced the withdrawal of Lartruvo (olaratumab) injection from the market.
    - Lartruvo is being withdrawn from the market following the failure of the phase 3 ANNOUNCE clinical trial, in which Lartruvo did not improve survival for patients.
    - No new patients should receive Lartruvo outside of participation in ongoing clinical trials.
    - Eli Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market.
- The FDA approved Lartruvo, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
    - Lartruvo was approved under the FDA's accelerated approval program in October 2016. As a condition of approval, Eli Lilly conducted a larger study, designed to confirm the clinical benefit of Lartruvo in these patients.
- Eli Lilly will provide more information regarding this withdrawal program directly to healthcare professionals in the coming weeks.